Moderna’s mRNA Access program (Nasdaq: MRNA) enables researchers to use its mRNA technology platform for research projects related to emerging and neglected infectious diseases.
“It takes a community of scientists and disease experts to develop novel vaccines to tackle our greatest public health threats,” said Hamilton Bennett, Moderna’s senior director, vaccine access and partnerships.
“mRNA Access was born of the idea that we are stewards of our platform, and by allowing researchers to access that platform, and leverage the preclinical, clinical, regulatory and manufacturing capabilities that we’ve created, we could accelerate the development of novel vaccines,” Bennett said.
Get the full story from our sister site, Drug Discovery & Development.